The invention provides treating cachexia and eating disorders in humans and veterinary animals by administering a composition including: (i) cyproheptadine (CYP) and (ii) a cannabis compound selected from the group of cannabidiol (CBD) and mixtures of CBD and up to 50% tetrahydrocannabinol (THC).